Related Experiment Video
Updated: Aug 18, 2026

Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
Published on: September 30, 2014
Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins
1Departments of Medical Microbiology and Medicine, Creighton University School of Medicine, Omaha, Nebraska 68178-0213.
Abstract:
The emergence of resistance to multiple beta-lactam antibiotics is a major problem in patients infected with organisms that characteristically produce inducible beta-lactamases--e.g., species of Pseudomonas, Enterobacter, Serratia, Citrobacter, indole-positive Proteus, and Providencia. Resistance has emerged in 14%-56% of patients infected with these organisms and treated with one of the newer cephalosporins. The emergence of resistance has been associated with clinical failure or relapse in 25%-75% of these patients. Combination therapy appears to have little impact on rates of resistance or its clinical consequences. Multiply resistant organisms have spread widely in some hospitals, and this trend has been correlated closely with the extent of use of the newer cephalosporins. The magnitude of the problem is frequently underestimated because many properly performed susceptibility tests fail to detect resistance when it is actually present and because some methods used to calculate rates minimize the impact of the emergence of resistance among organisms with inducible beta-lactamases.
Insights
Antibiotic resistance to beta-lactam drugs is a growing concern in hospitals. This resistance, often missed by standard tests, leads to treatment failures in patients with specific bacterial infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Beta-lactam antibiotics are crucial for treating bacterial infections.
- Inducible beta-lactamases are enzymes produced by certain bacteria that confer resistance to beta-lactam antibiotics.
- Emergence of multidrug resistance is a significant challenge in clinical settings.
Observation:
- Resistance to newer cephalosporins has emerged in 14%-56% of patients infected with organisms producing inducible beta-lactamases.
- This resistance is linked to clinical failure or relapse in 25%-75% of cases.
- Widespread use of newer cephalosporins correlates with the spread of multidrug-resistant organisms in hospitals.
Findings:
- Combination therapy shows limited impact on resistance rates or clinical outcomes.
- Standard susceptibility testing may fail to detect inducible beta-lactamase-mediated resistance.
- Calculation methods for resistance rates can underestimate the problem's true magnitude.
Implications:
- Clinical management of infections caused by inducible beta-lactamase-producing organisms requires careful consideration of antibiotic resistance.
- Improved diagnostic methods are needed to accurately detect resistance.
- Strategies to curb the spread of multidrug-resistant bacteria are essential, especially in hospital environments.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Development of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial DNA Synthesis
Clinical Significance of Antibiotic Resistance

